Generate Biomedicines applies machine learning and generative biology to design novel proteins and therapeutic candidates. Rather than only screening existing molecular libraries, it seeks to generate new biological molecules optimized for desired functions. Its work is aimed at drug discovery and biotherapeutic development partners and programs in the broader life-sciences pipeline.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 8.8 | — | -53.3 | — |
| Q2 2025 | 10.1 | — | -64 | — |
| Q1 2026 | 7.2 | -18.1% | -69.2 | — |
| Q2 2026 | 6.3 | -37.7% | -67.3 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Preformed Line Products Company (PLPC), Nayax Ltd. (NYAX), Keel Infrastructure Corp. (KEEL), Innodata Inc. (INOD), Melco Resorts & Entertainment Limited (MLCO), BlackLine, Inc. (BL)